Tongkat Ali
Tongkat Ali scored 6.7 / 10 (👍 Worth trying) on the BioHarmony scale as a Adaptogenic herb (standardized Eurycoma longifolia root extract).
Tongkat Ali is a Southeast Asian Eurycoma longifolia root extract with moderate evidence for testosterone and stress support. Tambi 2012 normalized testosterone into the reference range in 90.8% of hypogonadal men after 200 mg/day for 1 month, while newer reviews still rate the broader booster category as uncertain.
What is Tongkat Ali?
Tongkat Ali is a standardized extract of Eurycoma longifolia root, a bitter Southeast Asian botanical used for libido, male vitality, stress resilience, and age-related testosterone support. The practical version worth discussing is not random root powder. It is a verified hot-water extract like Physta or LJ100, where eurycomanone and related quassinoids are measured.
The best human signal is not "more testosterone for everyone." Tongkat Ali performs more like a responder-dependent nudge for men with low or borderline testosterone, high SHBG, high stress load, or aging-male symptoms. In Tambi 2012, 200 mg/day standardized extract for 1 month moved 90.8% of hypogonadal men into the normal testosterone range. In Talbott 2013, 200 mg/day for 4 weeks improved salivary cortisol, testosterone-to-cortisol ratio, and several mood-state domains in moderately stressed adults.
The 2024 to 2026 update does not turn Tongkat Ali into a universal testosterone booster. Morgado 2024 rated Eurycoma longifolia as only possibly effective within a broader testosterone-booster review, while Muniandy 2025 added a new menopause-quality-of-life RCT rather than resolving the male-performance evidence gap. Safety is also more complicated than the supplement marketing suggests: EFSA 2021 did not establish Physta safety because of animal genotoxicity findings, and FDA sexual-enhancement warnings make product quality a real concern in this category.
Terminology
For regulatory context, see the EFSA 2021 novel-food opinion.
- Eurycoma longifolia: Botanical name for Tongkat Ali, also called longjack or Malaysian ginseng.
- Physta: Standardized hot-water Eurycoma longifolia root extract used in several human trials.
- LJ100: 100:1 hot-water Tongkat Ali extract used in commercial standardized products.
- Eurycomanone: Main quassinoid marker compound used to standardize Tongkat Ali extracts; see Ahmad 2018.
- Quassinoid: Bitter triterpenoid lactone class that includes eurycomanone and related Tongkat Ali actives.
- Glycosaponin: Saponin-glycoside fraction in Physta that is often discussed in stress-axis and cortisol positioning.
- SHBG: Sex hormone-binding globulin, a blood protein that binds testosterone and lowers free testosterone availability.
- LH: Luteinizing hormone, the pituitary signal that tells Leydig cells in the testes to produce testosterone.
- FSH: Follicle-stimulating hormone, a pituitary hormone involved in sperm production and Sertoli-cell function.
- HPG axis: Hypothalamic-pituitary-gonadal axis, the hormone-control loop connecting brain signaling to gonadal hormone production.
- HPA axis: Hypothalamic-pituitary-adrenal axis, the stress-response loop involved in cortisol regulation.
- POMS: Profile of Mood States, a mood questionnaire used in Talbott 2013.
- T:C ratio: Testosterone-to-cortisol ratio, used as a rough anabolic-to-catabolic stress marker in sports endocrinology.
- NOAEL: No-observed-adverse-effect level. EFSA could not establish one for Physta from the submitted safety package.
- Drug-induced liver injury: Liver damage caused by a substance or medication; LiverTox lists rare possible Tongkat Ali involvement.
How do you take Tongkat Ali?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 2 routes and 6 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral capsule | Standardized hot-water root extract (Physta or LJ100) | 100 to 300 mg/day standardized extract; 200 mg/day is the most common human-trial dose | 200 to 600 mg/day, usually once in the morning |
| Oral root powder | Dried Eurycoma longifolia root powder or decoction | No modern RCT-backed clinical range | 1 to 5 g/day in traditional Malaysian-style decoction use |
Protocols
Clinical hypogonadal protocol Clinical
- Dose
- 200 mg/day Physta standardized extract
- Frequency
- Daily, single morning dose
- Duration
- 4 weeks minimum; retest total testosterone, free testosterone, SHBG, estradiol, and symptoms at week 4
Based on Tambi 2012 in late-onset hypogonadal men. Treat it as adjunctive support, not replacement for medical evaluation.
Stress and cortisol protocol Clinical
- Dose
- 200 mg/day Physta standardized extract
- Frequency
- Daily, single morning dose
- Duration
- 4 weeks
Based on Talbott 2013 in moderately stressed adults. The endpoint is stress-hormone and mood support, not bodybuilding.
Aging male plus training protocol Clinical
- Dose
- 200 mg/day Eurycoma longifolia extract
- Frequency
- Daily with concurrent training 3x/week
- Duration
- 6 months
Based on Leitão 2021 in men with androgen deficiency of aging males. The strongest signal came from the combined training plus extract condition.
Huberman-era community protocol Anecdotal
- Dose
- 400 mg/day Physta or LJ100
- Frequency
- Daily, single morning dose
- Duration
- 8 to 12 weeks on, then reassess
Popularized through the Tongkat Ali plus Fadogia Agrestis stack. This is an upward extrapolation from lower-dose clinical studies.
Cycled community protocol Anecdotal
- Dose
- 200 to 400 mg/day
- Frequency
- 5 days on, 2 days off, or 8 weeks on and 2 weeks off
- Duration
- Indefinite only with periodic breaks and lab monitoring
No clinical evidence proves cycling is necessary. Cycling is a caution hedge against unknown long-term use, not an optimized protocol.
Acute stress or travel use Anecdotal
- Dose
- 200 mg morning dose
- Frequency
- Daily during the acute window
- Duration
- 7 to 14 days
Short-window use targets stress tone and subjective resilience. It is not long enough to judge testosterone endpoints.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
What are the benefits of Tongkat Ali?
Upside contribution: 2.30
| Dimension | Weight | Band | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | Strong | 0.875 | |
| Breadth | 15% | Strong | 0.525 | |
| Evidence | 25% | Strong | 0.875 | |
| Speed | 10% | Moderate | 0.310 | |
| Durability | 10% | Limited | 0.220 | |
| Bioindividuality | 15% | Moderate | 0.495 | |
| Total | 3.300 | |||
| Baseline offset (constant) | −1.000 | |||
| Effective upside contribution | 2.300 |
Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.
Upside Rationale
Tongkat Ali crosses into strong-recommend territory because the human evidence for testosterone, libido, and stress support is genuinely good for the right user, and the traditional-use history reinforces it. Leisegang 2022 confirms the main direction of benefit across multiple RCTs, and Tambi 2012 shows where that signal lands hardest in real use. Mechanistically, Eurycoma longifolia shifts stress hormones, androgen signaling, and sexual-function markers, which makes it plausible across several BioHarmony use cases. The strength is clearest when the goal matches morning libido, mood, sleep, cortisol pattern, testosterone labs, training response, and side effects. It is weaker for vague optimization, since some claims hinge on specific extracts or lower-baseline users. Run it as a specific, measured, time-bounded experiment and the upside is real.
Efficacy (Strong): Tongkat Ali sits at the lower edge of the SM-032 moderate-to-large band on Tambi 2012, where 90.8 percent of 76 late-onset hypogonadal men reached normal testosterone after one month at 200 mg/day of standardized extract. Leisegang 2022 pooled five randomized trials and found a significant total-testosterone signal concentrated in hypogonadal men, and Leitao 2021 added a six-month randomized trial improving erectile function alongside testosterone. SM-061 anchors this dimension on real clinical magnitude, and Tongkat Ali delivers that magnitude only inside a defined responder group: Morgado 2024 classifies Eurycoma longifolia as merely possibly effective, and healthy eugonadal men gain little.
Breadth of benefits (Strong): Tongkat Ali carries three lanes that each own a named human endpoint, which is the several-validated-lanes-with-thinner-edges band. Androgen availability rests on Tambi 2012, Leisegang 2022 and Leitao 2021; stress physiology on Talbott 2013, where 200 mg/day for four weeks lowered salivary cortisol and improved mood states in 63 adults; sexual well-being on Ismail 2012 and George 2014. Muniandy 2025 adds a 112-completer menopause quality-of-life result that widens Tongkat Ali modestly. Muscle, fertility and sleep claims stay secondary and unmeasured, and every lane traces back to one androgen-and-cortisol root rather than a genuinely systemic mechanism.
Evidence quality (Strong): Tongkat Ali sits at the floor of the 3.5 to 4.4 solid-signal band of SM-050, after a sponsor trim. The literature carries multiple small randomised trials, the Leisegang 2022 meta-analysis of five of them, Chen 2014 for safety, and Muniandy 2025 for a newer female endpoint, plus a cited Southeast Asian use record in Rehman 2016. Against that, Morgado 2024 rates the compound only possibly effective, samples are small and windows short, and the pivotal trials run on Physta, the branded extract whose maker benefits, which triggers the modest evidence-integrity discount of SM-064 rather than a safety adjustment.
Speed of onset (Moderate): Tongkat Ali fits the one-to-three-week band of the SM-066 speed ladder. Talbott 2013 measured salivary cortisol and mood changes at four weeks, and Tambi 2012 measured testosterone normalization at one month, so every controlled endpoint attached to Tongkat Ali needs roughly a month. The packet reports subjective libido and energy shifts inside the first week, but the same packet flags those reports as uncontrolled and expectation-sensitive, and the ladder explicitly discounts a first mover that is not a clean felt effect. Tongkat Ali therefore scores above the slow biomarker band and well below the minutes-to-hours band occupied by stimulants.
Durability (Limited): Tongkat Ali loses its effect once dosing stops, which is squarely the needs-continued-use band. The packet states the effect usually fades over one to three weeks after discontinuation and that no permanent HPG recalibration is documented. Chen 2014 found no doping-pattern testosterone-to-epitestosterone shift after six weeks at 400 mg/day, reinforcing that Tongkat Ali is not building a lasting endocrine change. What persists is nothing: free testosterone availability, LH signaling and cortisol tone track exposure. A one-to-three-week fade is at the slower end of that band, which is why Tongkat Ali sits in its upper half rather than at the floor.
Bioindividuality (Moderate): Tongkat Ali sits at the top of the 2.5 to 3.4 band, where roughly half respond and the predictor is only partly usable. The packet names the strong-responder profile precisely, men over 35, measured low or borderline testosterone, high sex hormone-binding globulin, chronic stress load, and men leaving a caloric deficit or overtraining, and the predictors are ordinary blood tests a reader can order. Against the 3.5 to 4.4 band, Tongkat Ali fails the clear-majority test, because healthy eugonadal men under 30 are named as weak responders and unmeasured symptoms often turn out to be sleep apnea, hypothyroidism or obesity.
What are the risks & downsides of Tongkat Ali?
Downside contribution: 0.92 (safety risks weighted extra)
| Dimension | Weight | Band | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | Low | 0.630 | |
| Side effects | 15% | Low | 0.315 | |
| Cost premium | 5% | Low | 0.090 | |
| Effort | 5% | Negligible | 0.065 | |
| Opportunity | 5% | Low | 0.110 | |
| Dependency | 15% | Negligible | 0.180 | |
| Reversibility | 25% | Negligible | 0.300 | |
| Total | 1.690 | |||
| Harm subtotal × 1.4 | 1.995 | |||
| Opportunity subtotal × 1.0 | 0.265 | |||
| Combined downside | 2.260 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.920 |
Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.
Cost premium: premium over the cheapest legitimate route, not price.
Downside Rationale
Tongkat Ali's downside is real but light: extract quality, overstated claims, and stimulation in the wrong user, not a blanket danger claim. Talbott 2013 is the most useful caution anchor in the verified pool, and the broader tradeoff is that some claims come from specific extracts or lower-baseline users. Risk depends on context: anxiety, insomnia, stimulant stacking, hormone-sensitive conditions, liver concerns, and adulterated extracts can change the equation. A modest or uncertain upside has to clear a higher bar when the user has contraindications, poor tracking, or unrealistic expectations. In practice, run a narrow trial with conservative dosing and a stop rule tied to morning libido, mood, sleep, cortisol pattern, testosterone labs, training response, and side effects.
Safety (Low): Tongkat Ali shows no demonstrated intrinsic catastrophic mechanism, so the SM-019 floor does not apply, but two named flags keep Tongkat Ali above the benign floor. EFSA 2021 declined to establish safety for Physta after positive animal genotoxicity findings and could set no NOAEL, and LiverTox 2024 lists rare possible liver injury. Against that, Chen 2014 found no liver or renal change at 400 mg/day for six weeks, twice the clinical dose, and a human safety database exists, so no SM-072 aggravator applies. Adulterated male-enhancement product is extrinsic and routed to the sourcing caveat under SM-055.
Side effects (Low): Tongkat Ali produces an activation cluster common enough to name and to cause discontinuation, the meaningful-minority band. The packet lists insomnia, irritability, headache, restlessness, libido surges, acne flares and mild GI upset, with evening dosing the single most common way users make Tongkat Ali feel worse than it is. Men prone to high estradiol symptoms may notice water retention, nipple sensitivity or mood change as testosterone availability rises. Almost everything resolves on dose reduction, morning-only timing or stopping. Per SM-022 the rare liver signal is scored once in Safety and is not restated here, so Tongkat Ali sits just inside this band.
Cost premium (Low): Tongkat Ali costs roughly 20 to 40 dollars a month for verified Physta or LJ100 at 200 to 400 mg/day, placing it in the ordinary-ongoing-cost band of the SM-066 financial ladder. SM-007a and SM-026 score the premium over the cheapest legitimate route to the same exposure, and for Tongkat Ali no cheaper equivalent exists: bulk root powder is explicitly not dose-equivalent, carries active-marker and heavy-metal uncertainty, and matches none of the pivotal trials. Tongkat Ali therefore carries no branded premium of the kind that pushes C15 upward, and the absolute figure is unremarkable for a supplement.
Effort (Negligible): Tongkat Ali is close to the passive floor of the effort ladder: one capsule taken once in the morning, typically 200 mg/day, with no fasting window, device, timing puzzle or stacking requirement. The packet places the only real burden on responsible measurement, namely a baseline panel of total testosterone, free testosterone, sex hormone-binding globulin and estradiol with a retest after four to twelve weeks. That is a handful of actions per cycle rather than a daily task, so Tongkat Ali stays just above the under-a-minute floor without reaching the few-minutes-a-day band that weekly or repeated actions occupy.
Opportunity cost (Low): Tongkat Ali sits in the band where a concrete better-evidenced alternative exists in the same category, which the SM-066 ladder places alongside ashwagandha and metformin. The packet names the displacement risk directly: men reach for Tongkat Ali instead of sleep apnea screening, fat loss, alcohol reduction, progressive training or a real hypogonadism evaluation, and testosterone therapy is the guideline-backed option when hypogonadism is genuine. Tongkat Ali also competes head-on with ashwagandha for the stress-modulator slot. Tongkat Ali stacks cleanly with training, creatine and zinc repletion, so no evidence shows Tongkat Ali blunting a better lever.
Dependency (Negligible): Tongkat Ali has no craving, tolerance or withdrawal syndrome at standardized doses, which places it in the floor band. The packet states plainly that stopping returns the user to baseline rather than below it, and SM-066 is explicit that a benefit fading on discontinuation belongs to Durability and is never scored here. The only named reason Tongkat Ali sits marginally above the absolute floor is psychological: the packet describes users attributing every good workout or libido bump to the capsule. That is a mild pull, not the physiological discontinuation syndrome the next band up requires, so Tongkat Ali stays low.
Reversibility (Negligible): Tongkat Ali clears cleanly with no named durable-harm carve-out, the top band of the corrected SM-067 reversibility ladder. Ahmad 2018 reports that eurycomanone is not long-retained, and Chen 2014 found no doping-pattern testosterone-to-epitestosterone shift after six weeks at 400 mg/day, so Tongkat Ali does not suppress endogenous production the way exogenous androgens can. The hormonal and stress signal fades over days to weeks once Tongkat Ali stops. Loss of benefit is routed to Durability per SM-046, and the unresolved EFSA genotoxicity question is scored in Safety, not restated here as a permanence claim.
Is Tongkat Ali worth it?
Tongkat Ali is a 6.5–7.0/10 fit for men with low-normal testosterone, stress-linked libido issues, or training goals who can verify product quality and labs, because Tongkat Ali has moderate evidence for testosterone and stress support, but it is responder-dependent. Leisegang 2022 gives the strongest anchor, while Tambi 2012 adds useful context without closing the case. The honest gap is simple: many libido, strength, and hormone claims come from small studies, specific extracts, or lower-baseline users. That puts Tongkat Ali in the tracked-experiment category, not the automatic-staple category. In practice, Tongkat Ali makes the most sense when you monitor morning libido, mood, sleep, cortisol pattern, testosterone labs, training response, and side effects and avoid treating Tongkat Ali like a universal testosterone booster.
✅ Best for: Men over 35 with measured low or borderline testosterone, high SHBG, elevated cortisol load, age-related libido decline, or training blocks where stress is suppressing androgen tone. Tongkat Ali is most defensible after sleep, resistance training, protein, body composition, vitamin D, zinc, alcohol, and sleep apnea have already been addressed. Use verified Physta or LJ100, start with 200 mg/day in the morning, and retest labs after 4 to 12 weeks. It may also be worth cautious exploration for peri/post-menopausal quality of life after Muniandy 2025, but that use case is newer and narrower.
❌ Avoid if: You are pregnant, nursing, under 18, have hormone-sensitive cancer, have unexplained high PSA or prostate symptoms, are on TRT without estradiol monitoring, or are taking immunosuppressants without clinician input. Avoid Tongkat Ali if you want a substitute for diagnosis, testosterone therapy when medically indicated, fertility care, or lifestyle repair. Athletes should be careful because WADA does not need to name Tongkat Ali for contaminated supplements to create risk. Also avoid unverified male-enhancement products, bulk root powders, and brands without current third-party testing.
What is Tongkat Ali best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Hormonal / Endocrine: 6.5/10
Score: 6.5/10The hormonal case for Tongkat Ali is 6.5/10 because Talbott 2013 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: the cited study meta-analysis found a significant total-testosterone signal in men, the cited study reported 90.8% testosterone normalization in hypogonadal men, and. That does not make Tongkat Ali a targeted hormonal treatment. The report's best evidence is mostly small human trials, extract-specific data, and baseline-dependent hormone response, so the score is directional rather than settled. Track lab work, libido, sleep, and mood, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Stress / Resilience: 6.5/10
Score: 6.5/10Tongkat Ali's 6.5/10 stress-resilience score starts with Leisegang 2022, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: the cited study reported lower salivary cortisol, better testosterone-to-cortisol ratio, and Profile of Mood States improvements after 200 mg/day for 4 weeks. That does not make Tongkat Ali a targeted stress-resilience treatment. The report's best evidence is mostly small human trials, extract-specific data, and baseline-dependent hormone response, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Libido / Sexual Health: 6.3/10
Score: 6.3/10Tongkat Ali earns 6.3/10 for libido because Leisegang 2022 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: the cited study used the correct the indexed paper for phytoandrogenic review support, while the cited study reported sexual well-being improvements with. That does not make Tongkat Ali a targeted libido treatment. The report's best evidence is mostly small human trials, extract-specific data, and baseline-dependent hormone response, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Fertility (Male): 5.3/10
Score: 5.3/10For fertility-male, Tongkat Ali lands at 5.3/10 because Tambi 2012 supports the strongest part of the claim. The existing rationale points to this narrower claim: the cited study and the cited study support male sexual or senior-function outcomes, and animal sperm data add mechanism support, but the. That does not make Tongkat Ali a targeted fertility-male treatment. The report's best evidence is mostly small human trials, extract-specific data, and baseline-dependent hormone response, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Geriatric / Aging Population: 6.0/10
Score: 6.0/10Tongkat Ali's 6.0/10 geriatric score starts with Tambi 2012, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: Age-related testosterone decline is the clearest responder profile. the cited study, the cited study, and Leitão 2021 all fit older or aging-male. That does not make Tongkat Ali a targeted geriatric treatment. The report's best evidence is mostly small human trials, extract-specific data, and baseline-dependent hormone response, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Muscle Growth / Hypertrophy: 5.5/10
Score: 5.5/10The practical muscle-growth read on Tongkat Ali is 5.5/10 because Leisegang 2022 anchors the strongest signal. The existing rationale points to this narrower claim: the cited study is the main lean-mass citation, with support from aging-male and senior trials. Evidence does not justify treating Tongkat Ali. That does not make Tongkat Ali a targeted muscle-growth treatment. The report's best evidence is mostly small human trials, extract-specific data, and baseline-dependent hormone response, so the score is directional rather than settled. Track body composition, strength, soreness, and training logs, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Energy / Fatigue: 6.0/10
Score: 6.0/10On energy, Tongkat Ali deserves 6.0/10 because Tambi 2012 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Energy claims are mostly downstream of stress, mood, and testosterone-to-cortisol changes rather than direct fatigue trials. the cited study and the cited. That does not make Tongkat Ali a targeted energy treatment. The report's best evidence is mostly small human trials, extract-specific data, and baseline-dependent hormone response, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Mood / Emotional Regulation: 6.0/10
Score: 6.0/10For mood, Tongkat Ali lands at 6.0/10 because Talbott 2013 supports the strongest part of the claim. The existing rationale points to this narrower claim: the cited study reported Profile of Mood States improvements in tension, anger, and confusion. the cited study found menopause quality-of-life improvement, with. That does not make Tongkat Ali a targeted mood treatment. The report's best evidence is mostly small human trials, extract-specific data, and baseline-dependent hormone response, so the score is directional rather than settled. Track mood score, irritability, and stress recovery, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Strength / Power: 5.8/10
Score: 5.8/10A 5.8/10 for strength-power fits Tongkat Ali because Talbott 2013 supports direction more than certainty. The existing rationale points to this narrower claim: the cited study reported lean-mass and strength gains in trained men, while the cited study found force improvements in physically active seniors. That does not make Tongkat Ali a targeted strength-power treatment. The report's best evidence is mostly small human trials, extract-specific data, and baseline-dependent hormone response, so the score is directional rather than settled. Track body composition, strength, soreness, and training logs, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Recovery / Repair: 5.5/10
Score: 5.5/10Tongkat Ali earns 5.5/10 for recovery-repair because Tambi 2012 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: The recovery case is indirect: the cited study showed a better testosterone-to-cortisol profile in stressed adults, which can matter during overreaching. No. That does not make Tongkat Ali a targeted recovery-repair treatment. The report's best evidence is mostly small human trials, extract-specific data, and baseline-dependent hormone response, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Body Composition / Fat Loss: 5.2/10
Score: 5.2/10The body-composition case for Tongkat Ali is 5.2/10 because Leisegang 2022 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: the cited study reported modest lean-mass gain, and androgen support can help older or low-testosterone men train harder. Direct fat-loss evidence is. That does not make Tongkat Ali a targeted body-composition treatment. The report's best evidence is mostly small human trials, extract-specific data, and baseline-dependent hormone response, so the score is directional rather than settled. Track body composition, strength, soreness, and training logs, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
| Use Case | Score | Summary |
|---|---|---|
| ⚖️ Sleep Quality | 4.8 | Sleep benefit is indirect through stress tone. In practice, evening dosing can disrupt sleep, and insomnia is one of the most consistent community side effects, so morning-only dosing matters. |
| ⚖️ Endurance / Cardio | 4.8 | Endurance evidence is limited. Testosterone-to-cortisol changes might help overreached athletes, but no robust VO2max, lactate-threshold, or endurance-performance RCT supports a higher score. |
| ○ Anxiety | 4.5 | Anxiety support is inferred from stress-hormone and POMS data rather than anxiety-specific trials. Tongkat Ali can also feel activating, so anxious users may worsen if dosing is too high or too late. |
| ○ Sleep Architecture (Deep/REM) | 4.5 | No direct polysomnography, wearable sleep-stage, or sleep-architecture trial was found. Any sleep effect should be treated as secondary to cortisol timing and arousal state. |
| ○ Circadian Rhythm / Chronobiology | 4.5 | There is no direct circadian-rhythm evidence. Morning dosing is sensible because Tongkat Ali can feel activating and because evening dosing is more likely to impair sleep. |
| ○ VO2 Max | 4.5 | No direct VO2max trial was identified. Tongkat Ali may support training quality in specific responders, but it is not an aerobic-capacity intervention. |
| ○ Reaction Time / Coordination | 4.5 | No direct reaction-time evidence was identified. Any alertness improvement is subjective and likely mediated through stress, mood, or libido rather than validated psychomotor testing. |
| ○ HRV / Vagal Tone / Autonomic Balance | 4.5 | Stress-axis data suggest a possible autonomic effect, but no direct HRV RCT was identified. Pairing with HRV biofeedback has more direct rationale than relying on Tongkat Ali alone. |
| ○ Healthspan | 4.5 | Healthspan support is indirect through stress, libido, mood, and androgen tone in older men. Evidence does not reach the standard of exercise, sleep, creatine, or cardiometabolic interventions. |
| ○ Bone / Joint Health | 4.5 | Bone support is inferred from androgen biology and male-osteoporosis reviews, not dedicated human bone-outcome trials. This is not a joint-pain intervention. |
| ○ Depression | 4.0 | Talbott 2013 included mood-state outcomes but did not establish Tongkat Ali as a depression intervention. Depression-specific RCTs, clinical diagnostic endpoints, and long-term safety data are absent. |
| ○ Flexibility / Mobility | 4.0 | No direct evidence supports flexibility or mobility. Testosterone tone may indirectly support training adaptation, but that does not translate into a mobility-specific claim. |
| ○ Immune Function | 4.0 | Preliminary immune-modulation signals exist, but immune support is not a primary indication. Immunosuppressed users should be cautious because immune activation could be counterproductive. |
| ○ Injury Recovery | 4.0 | Injury recovery is indirect through training tolerance and testosterone-to-cortisol changes. No dedicated injury-recovery RCT was identified. |
| ○ Metabolic Health | 3.8 | Metabolic claims are indirect through testosterone support in older men. No strong human glucose, insulin, or body-composition trial supports Tongkat Ali as a metabolic-health tool. |
| ○ Anti-Inflammatory | 3.8 | Cortisol reduction is adjacent to inflammation control, but no direct CRP, IL-6, or clinical inflammatory-disease RCT supports a higher score. |
| ○ Kidney Function | 3.8 | Standardized-extract trials such as Chen 2014 did not show clinically meaningful kidney-marker changes over short windows. No kidney-benefit evidence supports a higher score. |
| ○ Cognition / Focus | 3.5 | Mood and arousal changes may improve perceived focus in some stressed users. No direct cognitive RCTs, attention endpoints, or memory endpoints justify stronger claims. |
| ○ Memory | 3.5 | No direct memory RCT data were identified. Any memory claim would be extrapolated from mood and stress changes and should remain low-confidence. |
| ○ Flow State / Peak Mental Performance | 3.5 | Flow-state effects are indirect through mood, arousal, and confidence. No direct flow or performance-psychology RCT supports a stronger score. |
| ○ Blood Sugar / Glycemic Control | 3.5 | No direct glycemic RCT data were identified. Animal and mechanistic signals are not enough for a clinically useful blood-sugar score. |
| ○ Antioxidant / Oxidative Stress | 3.5 | In-vitro antioxidant activity appears in reviews such as Rehman 2016, but human oxidative-stress biomarker trials are not strong enough to make this a main use case. |
| ○ Mitochondrial | 3.5 | Mitochondrial benefit is indirect through training, androgen status, and stress tone. There are no direct human mitochondrial endpoints for Tongkat Ali. |
| ○ Cardiovascular | 3.2 | Short-term standardized-extract trials generally do not show major liver, kidney, or lipid shifts, but there is no cardiovascular endpoint evidence. Estradiol can rise through aromatization in susceptible men. |
| ○ Hair / Nail Health | 3.2 | The androgenic mechanism cuts both ways. Tongkat Ali may support body-hair androgen tone but could worsen androgenetic alopecia in DHT-sensitive men. |
| ○ Fertility (Female) | 3.0 | Muniandy 2025 adds the first larger Physta menopause RCT signal for quality of life and sexual-domain improvement, but pregnancy and lactation remain excluded by EFSA 2021 and female fertility itself has not been validated. |
| ○ Neuroplasticity | 3.0 | No direct human neuroplasticity evidence was identified. Tongkat Ali should not be framed as a brain-rewiring or learning-enhancement supplement. |
| ○ Creativity / Divergent Thinking | 3.0 | No direct creativity data were identified. Tongkat Ali is not a creativity supplement, even if some users feel more driven or socially confident. |
| ○ Longevity / Lifespan | 3.0 | No longevity endpoint data exist. The mechanism is functional and short-lived, not a durable aging-pathway intervention. |
| ○ Liver / Detoxification | 3.0 | LiverTox lists Tongkat Ali as a rare possible cause of clinically apparent liver injury, while standardized-extract trials have not shown consistent liver-enzyme problems. This is a caution score, not a detox claim. |
| ○ Chronic Pain Management | 3.0 | Cortisol and stress modulation are chronic-pain-adjacent, but no direct pain RCT supports a therapeutic claim. |
| ○ Social Bonding / Empathy | 3.0 | Mood, libido, and confidence can alter social behavior, but no social-bonding evidence exists. This remains anecdotal and indirect. |
Compare Tongkat Ali with
Frequently Asked Questions
What is Tongkat Ali and how does it work?
Tongkat Ali is a Southeast Asian Eurycoma longifolia root extract that appears to work through androgen and stress-hormone pathways. Standardized extracts concentrate eurycomanone and other quassinoids, which are studied for effects on testosterone availability, LH signaling, and cortisol tone. Tambi 2012 supports the low-testosterone use case, while Talbott 2013 supports the stress-hormone angle. Effects are strongest when baseline testosterone or stress markers are actually off.
What is the best dose of Tongkat Ali?
The best-supported dose is 200 mg/day of standardized Physta or LJ100, taken once in the morning. That is the dose used in Tambi 2012 for late-onset hypogonadism and Talbott 2013 for stress. The common 400 mg/day community dose is an extrapolation, not a directly validated upgrade. Avoid evening dosing because insomnia and an overactivated feel are common practical problems.
Does Tongkat Ali actually increase testosterone?
Yes, but mainly in the right population. Tambi 2012 reported that 90.8% of hypogonadal men reached normal testosterone values after 1 month of 200 mg/day standardized extract. Leisegang 2022 found a significant total-testosterone signal across five RCTs in its meta-analysis. In healthy young men with normal free testosterone, the effect is usually weaker and less predictable.
Is Tongkat Ali safe for the liver?
Verified standardized extracts look low-risk short-term, but liver safety is not settled for high-dose chronic use or poor-quality products. Chen 2014 found no liver or kidney-function problems after 400 mg/day for 6 weeks in recreational athletes. LiverTox still lists rare possible liver injury, and EFSA 2021 did not establish Physta safety because of animal genotoxicity findings.
How long does Tongkat Ali take to work?
Plan on 2 to 4 weeks for measurable stress and hormone changes, with some subjective libido or energy changes earlier. Talbott 2013 measured stress-hormone and mood changes after 4 weeks. Tambi 2012 measured testosterone normalization at 1 month. Effects usually fade after stopping, so the practical test is a 4 to 12 week trial with morning dosing and before-after labs.
Physta vs LJ100 vs root powder: which Tongkat Ali extract is best?
Physta and LJ100 are the safest defaults because they are standardized hot-water extracts used in or adjacent to the clinical literature. Root powder may match traditional use, but it is not dose-equivalent to a standardized extract. Ahmad 2018 supports eurycomanone as a key standardization marker, while authenticity studies like Fadzil 2018 show why generic products need verification. Buy based on testing, not macho label claims.
Can women take Tongkat Ali?
Non-pregnant women now have limited evidence, but Tongkat Ali is not a validated female-hormone tool yet. Muniandy 2025 found Physta 100 mg improved menopausal quality-of-life scores over 12 weeks, especially physical and sexual domains. That does not override EFSA 2021, which excluded pregnancy and lactation because safety was not established. Women should be more conservative than male-marketing pages imply.
What's the difference between Tongkat Ali and Fadogia Agrestis?
Tongkat Ali has a materially stronger human evidence base than Fadogia Agrestis. Tongkat Ali has small RCTs, human safety data, and testosterone-focused reviews such as Leisegang 2022. Fadogia remains mostly animal and anecdotal evidence. The popular stack treats them like equivalent halves, but they are not equivalent. If you are choosing one, Tongkat Ali with a verified extract is the more defensible starting point.
Who should avoid Tongkat Ali?
Avoid Tongkat Ali if you are pregnant, nursing, dealing with hormone-sensitive cancer, or using TRT without estradiol and symptom monitoring. Men with prostate concerns should involve a clinician rather than self-treating testosterone symptoms. Immunosuppressed users should be cautious because immune-modulation signals are not well mapped. Athletes should also treat supplement quality as the main anti-doping risk, since USADA holds athletes responsible for contaminated supplements.
What could change Tongkat Ali's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Large independent non-industry Western RCT replicates testosterone and stress findings in n>500 | Evidence 3.0 to 3.8; Bioindividuality 2.8 to 3.2 | 6.8 / 10 👍 Worth trying |
| Rigorous 12-month safety trial confirms no liver injury or clinically relevant genotoxicity at standard doses | Safety 2.2 to 1.5; Side effects 2.5 to 2.0 | 7.1 / 10 💪 Strong recommend |
| Human confirmatory study validates DNA-damage concern at near-clinical doses | Safety 2.2 to 3.5 | 6.0 / 10 👍 Worth trying |
| Independent bioequivalence trial shows generic eurycomanone-standardized extract matches Physta and LJ100 | Evidence 3.0 to 3.3; Cost 1.8 to 1.4 | 6.7 / 10 👍 Worth trying |
| Well-powered RCT in healthy eugonadal men under 30 shows null effect | Efficacy 3.0 to 2.5; Bioindividuality 2.8 to 2.3 | 6.2 / 10 👍 Worth trying |
| Community 400 to 600 mg/day dosing is linked to a new case series of hormonal or liver side effects | Safety 2.2 to 3.0; Side effects 2.5 to 3.2 | 6.0 / 10 👍 Worth trying |
| Well-designed female RCT replicates peri/post-menopausal libido and mood benefit | Breadth 3.0 to 3.5; Bioindividuality 2.8 to 3.3 | 6.7 / 10 👍 Worth trying |
Key Evidence Sources
- Morgado et al. 2024 - Do testosterone boosters really increase serum total testosterone? systematic review, International Journal of Impotence Research. 52 studies across 27 proposed testosterone boosters; Eurycoma longifolia categorized as possibly effective in late-onset hypogonadism and possibly effective in healthy men
- Muniandy et al. 2025 - Effect of Eurycoma longifolia water extract (Physta) on menopausal quality of life and mood states, World Journal of Clinical Cases. 112 completers; Physta 100 mg improved total MENQOL score and physical and sexual domains over 12 weeks
- Sukardiman et al. 2025 - Potential and mechanisms of indigenous Indonesian medicinal plants in treating sexual dysfunction, Heliyon. Broad systematic review and pharmacological network overview; Eurycoma longifolia mapped to erectile-dysfunction and steroid-hormone pathways
- Leisegang et al. 2022 - Eurycoma longifolia improves serum total testosterone in men: systematic review and meta-analysis, Medicina. Nine studies in systematic review; five RCTs in meta-analysis; total testosterone improved with strongest support in hypogonadal men
- Leitão et al. 2021 - Eurycoma longifolia and concurrent training in androgen deficiency of aging males, Maturitas. Six-month double-blind RCT in 45 men; extract plus concurrent training improved erectile function and total testosterone
- Tambi et al. 2012 - Standardised water-soluble extract of Eurycoma longifolia as testosterone booster for late-onset hypogonadism, Andrologia. 76 men with late-onset hypogonadism; 200 mg/day for 1 month; 90.8% showed normal testosterone after treatment
- Talbott et al. 2013 - Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects, JISSN. 63 moderately stressed adults; 200 mg/day for 4 weeks; cortisol down, testosterone-to-cortisol profile and mood state improved
- Henkel et al. 2014 - Tongkat Ali as a potential herbal supplement for physically active male and female seniors, Phytotherapy Research. Pilot study in physically active seniors; supports testosterone and muscular-force signal; PMID corrected away from George attribution
- George et al. 2014 - Phytoandrogenic properties of Eurycoma longifolia as natural alternative to testosterone replacement therapy, Andrologia. Correct George 2014 PMID per audit; review of testosterone-deficiency syndrome and Eurycoma longifolia phytoandrogenic data
- Ismail et al. 2012 - PHYSTA randomized clinical trial for quality of life and sexual well-being in men, Evidence-Based Complementary and Alternative Medicine. Randomized double-blind placebo-controlled trial of Physta in men, with quality-of-life and sexual well-being outcomes
- Chen et al. 2014 - Eurycoma longifolia does not affect urinary testosterone:epitestosterone ratio, liver, or renal function in recreational athletes, International Journal of Preventive Medicine. 13 male recreational athletes; crossover design; 400 mg/day for 6 weeks did not alter T:E ratio or liver and kidney markers
- Ahmad et al. 2018 - Bioavailability of eurycomanone in pure form and standardized Eurycoma longifolia water extract, Pharmaceutics. Pharmacokinetic and standardization study; eurycomanone is a key marker but animal PK cannot be directly extrapolated to humans
- Rehman et al. 2016 - Review on Eurycoma longifolia traditional uses, chemistry, pharmacology, and toxicology, Molecules. Traditional-use, chemistry, quassinoid, pharmacology, and toxicology review
- Fadzil et al. 2018 - Authenticity testing and detection of Eurycoma longifolia in commercial herbal products, Genes. Commercial product authenticity testing with bar-HRM analysis; supports supply-chain caution
- Abubakar et al. 2018 - Assessing product adulteration of Eurycoma longifolia herbal medicinal product using DNA barcoding and HPLC analysis, Pharmaceutical Biology. DNA barcoding and HPLC analysis of commercial products; supports authenticity and active-marker verification
- EFSA Panel on Nutrition, Novel Foods and Food Allergens 2021 - Safety of Eurycoma longifolia Jack root extract as a novel food. Safety not established for Physta due to positive genotoxicity findings; pregnancy and lactation excluded
- LiverTox 2024 - Tongkat Ali, NCBI Bookshelf. Clinical liver-safety summary; rare possible liver-injury reports and short-term trial safety context
- Chen et al. 2002 - Toxicity of some quassinoids from Eurycoma longifolia, Planta Medica. Toxicity-guided quassinoid work identifying eurycomanone as the most toxic component in the tested fractions
What does the evidence say about Tongkat Ali?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Morgado 2024, Muniandy 2025, Leisegang 2022, Leitão 2021, Tambi 2012, Talbott 2013, Henkel 2014, Ismail 2012, EFSA 2021, LiverTox 2024
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Rehman 2016, Bhat 2010, Malaysian Standard MS 2409:2011, Jaganath 2000, George 2014
Traditional Medicine Systems
Confidence: Medium
Citations: Rehman 2016, Ahmad 2018
Holistic Evidence for Tongkat Ali
The three lenses converge on Tongkat Ali as a vitality and reproductive-health botanical, but they disagree on certainty. Traditional and historical records show durable regional use, while modern trials identify a narrower responder profile: older, stressed, or hypogonadal users. The honest synthesis is practical: Tongkat Ali is worth a monitored trial for the right person using a verified extract, but it should not replace diagnosis, testosterone therapy when medically indicated, fertility care, sleep, training, or body-composition work.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Testosterone Total Baseline (pre-protocol)
- Testosterone Free During | Expected Up
- SHBG During | Expected Down
- Estradiol During | Expected Watch
- ALT During | Expected Stable
- AST During | Expected Stable
Pulse Dimensions to Watch
- Drive During | Expected Up | Primary
- Energy During | Expected Up | Secondary
- Calm During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Libido Scale 1-5 | During | Expected Up
- Irritability Scale 1-5 | During | Expected Watch
- Sleep Quality Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Marked irritability or aggression
- Insomnia with elevated resting HR
Other interventions for Hormonal
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.300 − 0.920 = 1.380
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.380 / 4.00) × 5 = 6.7 / 10
Further learning
Biohacking Testosterone Protocol: Powerful & Natural Optimization
Testosterone is an incredibly misunderstood yet vital hormone for both men and women. Contrary to popular belief, it's low testosterone that's especially dangerous. This…
Superior Herbs That Raise Testosterone, Balance Hormones, & Boost Performance (He Shou Wu, Pine Pollen, Blue Vervain, Shilajit & More)
What separates an average supplement routine from a superior one? Drawing from both ancient herbalism & modern performance science, Logan Christopher from Lost Empire…
